XML 33 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock Option Plan
12 Months Ended
Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Option Plan
STOCK OPTION PLAN
The Company established a stock option plan in 1993 (the “1993 Plan”) for the purpose of attracting and retaining executive officers and other key personnel. The 1993 Plan provides for grants of options to purchase up to 400,000 shares of common stock. The 1993 Plan authorizes the Compensation Committee of the Board of Directors to grant options at an exercise price which may not be less than the market value of the common stock on the date the option is granted.
At the annual meeting of the Company’s stockholders in 2004, the stockholders approved the adoption of the 2004 stock plan for the purpose of attracting and retaining executive officers, directors and other key personnel. The 2004 stock plan was subsequently amended by the Company’s stockholders at the 2008 Annual Meeting and further amended at the 2013 Annual Meeting (the “Amended 2004 Plan”). The Amended 2004 Plan, which terminates in 2023, provides for grants of options to purchase up to 2,000,000 shares of common stock as well as grants of up to 200,000 shares of common stock to directors. The Amended 2004 Plan authorizes the Compensation Committee of the Board of Directors to grant options at an exercise price which may not be less than the market value of the common stock on the date the option is granted.
Effective April 27, 2007, the Compensation Committee granted options to purchase 165,000 shares (27,560 incentive stock options and 137,440 nonqualified stock options) to thirteen Company officers and twelve Company Directors (the “2007 options”), which expire on April 26, 2017. The officers’ 2007 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ options were immediately exercisable. The exercise price of $54.17 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2007 Options to be $1.5 million, of which $1.3 million and $285,300 were the values assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $285,300 was expensed as of the date of grant. The expense for the officers’ options was recognized as compensation expense monthly during the four years the options vested.
Effective April 25, 2008, the Compensation Committee granted options to purchase 30,000 shares (all nonqualified stock options) to twelve Company directors (the “2008 Options”), which were immediately exercisable and expire on April 24, 2018. The exercise price of $50.15 per share was the closing market price of the Company’s common stock on the date of the award. Using the Black-Scholes model, the Company determined the total fair value of the 2008 Options to be $254,700. Because the directors’ options vested immediately, the entire $254,700 was expensed as of the date of grant. No options were granted to the Company’s officers in 2008.
Effective April 24, 2009, the Compensation Committee granted options to purchase 32,500 shares (all nonqualified stock options) to thirteen Company directors (the “2009 Options”), which were immediately exercisable and expire on April 23, 2019. The exercise price of $32.68 per share was the closing market price of the Company’s common stock on the date of the award. Using the Black-Scholes model, the Company determined the total fair value of the 2009 Options to be $222,950. Because the directors’ options vested immediately, the entire $222,950 was expensed as of the date of grant. No options were granted to the Company’s officers in 2009.
Effective May 7, 2010, the Compensation Committee granted options to purchase 32,500 shares (all nonqualified stock options) to thirteen Company directors (the “2010 Options”), which were immediately exercisable and expire on May 6, 2020. The exercise price of $38.76 per share was the closing market price of the Company’s common stock on the date of the award. Using the Black-Scholes model, the Company determined the total fair value of the 2010 Options to be $287,950. Because the directors’ options vested immediately, the entire $287,950 was expensed as of the date of grant. No options were granted to the Company’s officers in 2010.
Effective May 13, 2011, the Compensation Committee granted options to purchase 195,000 shares (65,300 incentive stock options and 129,700 nonqualified stock options) to fifteen Company officers and thirteen Company Directors (the “2011 options”), which expire on May 12, 2021. The officers’ 2011 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ 2011 options were immediately exercisable. The exercise price of $41.82 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2011 Options to be $1.6 million, of which $1.3 million and $297,375 were assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $297,375 was expensed as of the date of grant. The expense for the officers’ options is being recognized as compensation expense monthly during the four years the options vest.
Effective May 4, 2012, the Compensation Committee granted options to purchase 277,500 shares (26,157 incentive stock options and 251,343 nonqualified stock options) to fifteen Company officers and fourteen Company Directors (the “2012 options”), which expire on May 3, 2022. The officers’ 2012 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ 2012 Options were immediately exercisable. The exercise price of $39.29 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2012 Options to be $1.7 million, of which $1.4 million and $257,250 were assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $257,250 was expensed as of the date of grant. The expense for the officers’ options is being recognized as compensation expense monthly during the four years the options vest.
Effective May 10, 2013, the Compensation Committee granted options to purchase 237,500 shares (35,592 incentive stock options and 201,908 nonqualified stock options) to fifteen Company officers and fourteen Company Directors (the "2013 options"), which expire on May 9, 2023. The officers' 2013 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors' 2013 options were immediately exercisable. The exercise price of $44.42 per share was the closing market price of the Company's common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2013 Options to be $1.5 million, of which $1.2 million and $278,250 were assigned to the officer options and director options, respectively. Because the directors' options vested immediately, the entire $278,250 was expensed as of the date of grant. The expense for the officers' options is being recognized as compensation expense monthly during the four years the option was vested.
Effective May 9, 2014, the Compensation Committee granted options to purchase 200,000 shares (29,300 incentive stock options and 170,700 nonqualified stock options) to eighteen Company officers and twelve Company Directors (the “2014 options”), which expire on May 8, 2024. The officers’ 2014 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ 2014 Options were immediately exercisable. The exercise price of $47.03 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2014 Options to be $1.3 million, of which $1.2 million and $109,500 were assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $109,500 was expensed as of the date of grant. The expense for the officers’ options is being recognized as compensation expense monthly during the four years the options vest.
Effective May 8, 2015, the Compensation Committee granted options to purchase 225,000 shares (33,690 incentive stock options and 191,310 nonqualified stock options) to 19 Company officers and 14 Company Directors (the “2015 options”), which expire on May 7, 2025. The officers’ 2015 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ 2015 Options were immediately exercisable. The exercise price of $51.07 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2015 Options to be $1.6 million, of which $1.4 million and $125,300 were assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $125,300 was expensed as of the date of grant. The expense for the officers’ options is being recognized as compensation expense monthly during the four years the options vest.
Effective May 6, 2016, the Compensation Committee granted options to purchase 226,500 shares (24,248 incentive stock options and 202,252 nonqualified stock options) to 19 Company officers and 13 Company Directors (the “2016 options”), which expire on May 5, 2026. The officers’ 2016 Options vest 25% per year over four years and are subject to early expiration upon termination of employment. The directors’ 2016 Options were immediately exercisable. The exercise price of $57.74 per share was the closing market price of the Company’s common stock on the date of award. Using the Black-Scholes model, the Company determined the total fair value of the 2016 Options to be $1.2 million, of which $1.0 million and $151,125 were assigned to the officer options and director options, respectively. Because the directors’ options vested immediately, the entire $151,125 was expensed as of the date of grant. The expense for the officers’ options is being recognized as compensation expense monthly during the four years the options vest.
The following table summarizes the amount and activity of each grant, the total value and variables used in the computation and the amount expensed and included in general and administrative expense in the Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014.
SAUL CENTERS, INC.
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share data)
Stock options issued
 
 

 
 

 
 

 
 

 
 

 
 

 
 
 
 
 
 
 
 
 
 

 
Directors
Grant date
 
4/27/2007
 
4/25/2008
 
4/24/2009
 
5/7/2010
 
5/13/2011
 
5/4/2012
 
5/10/2013
 
5/9/2014
 
5/8/2015
 
5/6/2016
 
Subtotals
Total grant
 
30,000

 
30,000

 
32,500

 
32,500

 
32,500

 
35,000

 
35,000

 
30,000

 
35,000

 
32,500

 
325,000

Vested
 
30,000

 
30,000

 
32,500

 
32,500

 
32,500

 
35,000

 
35,000

 
30,000

 
35,000

 
32,500

 
325,000

Exercised
 
10,000

 
12,500

 
25,000

 
17,500

 
17,500

 
17,500

 
15,000

 
10,000

 
5,000

 

 
130,000

Forfeited
 
7,500

 
7,500

 

 
2,500

 
2,500

 

 

 

 

 

 
20,000

Exercisable at December 31, 2016
 
12,500

 
10,000

 
7,500

 
12,500

 
12,500

 
17,500

 
20,000

 
20,000

 
30,000

 
32,500

 
175,000

Remaining unexercised
 
12,500

 
10,000

 
7,500

 
12,500

 
12,500

 
17,500

 
20,000

 
20,000

 
30,000

 
32,500

 
175,000

Exercise price
 
$
54.17

 
$
50.15

 
$
32.68

 
$
38.76

 
$
41.82

 
$
39.29

 
$
44.42

 
$
47.03

 
$
51.07

 
$
57.74

 
 
Volatility
 
0.225

 
0.237

 
0.344

 
0.369

 
0.358

 
0.348

 
0.333

 
0.173

 
0.166

 
0.166

 
 
Expected life (years)
 
8.0

 
7.0

 
6.0

 
5.0

 
5.0

 
5.0

 
5.0

 
5.0

 
5.0

 
5.0

 
 
Assumed yield
 
4.39
%
 
4.09
%
 
4.54
%
 
4.23
%
 
4.16
%
 
4.61
%
 
4.53
%
 
4.48
%
 
4.54
%
 
3.75
%
 
 
Risk-free rate
 
4.65
%
 
3.49
%
 
2.19
%
 
2.17
%
 
1.86
%
 
0.78
%
 
0.82
%
 
1.63
%
 
1.50
%
 
1.23
%
 
 
Total value at grant date
 
$
285

 
$
255

 
$
223

 
$
288

 
$
298

 
$
257

 
$
278

 
$
110

 
$
125

 
$
151

 
$
2,270

Expensed in previous years
 
285

 
255

 
223

 
288

 
298

 
257

 
278

 

 

 

 
1,884

Expensed in 2014
 

 

 

 

 

 

 

 
110

 

 

 
110

Expensed in 2015
 

 

 

 

 

 

 

 

 
125

 

 
125

Expensed in 2016
 

 

 

 

 

 

 

 

 

 
151

 
151

Future expense
 

 

 

 

 

 

 

 

 

 

 

 
Officers
 
 
 
 
 
 
 
 

Grant date
 
4/27/2007
 
5/13/2011
 
5/4/2012
 
5/10/2013
 
5/9/2014
 
5/8/2015
 
5/6/2016
 
Subtotals
 
 
 
 
 
Grand Totals
Total grant
 
135,000

 
162,500

 
242,500

 
202,500

 
170,000

 
190,000

 
194,000

 
1,296,500

 
 
 
 
 
1,621,500

Vested
 
67,500

 
118,750

 
107,500

 
131,875

 
85,000

 
47,500

 

 
558,125

 
 
 
 
 
883,125

Exercised
 
67,500

 
92,915

 
91,205

 
68,750

 
31,250

 
6,250

 

 
357,870

 
 
 
 
 
487,870

Forfeited
 
67,500

 
43,750

 
135,000

 
30,625

 
1,250

 
1,875

 

 
280,000

 
 
 
 
 
300,000

Exercisable at December 31, 2016
 

 
25,835

 
16,295

 
63,125

 
53,750

 
41,250

 

 
200,255

 
 
 
 
 
375,255

Remaining unexercised
 

 
25,835

 
16,295

 
103,125

 
137,500

 
181,875

 
194,000

 
658,630

 
 
 
 
 
833,630

Exercise price
 
$
54.17

 
$
41.82

 
$
39.29

 
$
44.42

 
$
47.03

 
$
51.07

 
$
57.74

 
 
 
 
 
 
 
 
Volatility
 
0.233

 
0.330

 
0.315

 
0.304

 
0.306

 
0.298

 
0.185

 
 
 
 
 
 
 
 
Expected life (years)
 
6.5

 
8.0

 
8.0

 
8.0

 
7.0

 
7.0

 
7.0

 
 
 
 
 
 
 
 
Assumed yield
 
4.13
%
 
4.81
%
 
5.28
%
 
5.12
%
 
4.89
%
 
4.94
%
 
3.80
%
 
 
 
 
 
 
 
 
Risk-free rate
 
4.61
%
 
2.75
%
 
1.49
%
 
1.49
%
 
2.17
%
 
1.89
%
 
1.55
%
 
 
 
 
 
 
 
 
Gross value at grant date
 
$
1,339

 
$
1,366

 
$
1,518

 
$
1,401

 
$
1,350

 
$
1,585

 
$
1,137

 
$
9,696

 
 
 
 
 
$
11,966

Estimated forfeitures
 
62

 
368

 
845

 
280

 
169

 
142

 
87

 
1,953

 
 
 
 
 
1,953

Expensed in previous years
 
1,277

 
692

 
262

 
209

 

 

 

 
2,440

 
 
 
 
 
4,324

Expensed in 2014
 

 
217

 
157

 
284

 
197

 

 

 
855

 
 
 
 
 
965

Expensed in 2015
 

 
89

 
157

 
269

 
295

 
241

 

 
1,051

 
 
 
 
 
1,176

Expensed in 2016
 
 
 

 
97

 
269

 
295

 
361

 
175

 
1,197

 
 
 
 
 
1,348

Future expense
 

 

 

 
90

 
394

 
841

 
875

 
2,200

 
 
 
 
 
2,200

Weighted average term of remaining future expense
 
2.5

 
 years

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table below summarizes the option activity for the years 2016, 2015, and 2014:
 
2016
 
2015
 
2014
 
Shares
 
Weighted
Average
Exercise
Price
 
Shares
 
Weighted
Average
Exercise
Price
 
Shares
 
Weighted
Average
Exercise
Price
Outstanding at January 1
860,274

 
$
46.58

 
748,208

 
$
44.79

 
753,625

 
$
42.55

Granted
226,500

 
57.74

 
225,000

 
51.07

 
200,000

 
47.03

Exercised
(246,894
)
 
45.59

 
(112,934
)
 
43.67

 
(167,917
)
 
37.71

Expired/Forfeited
(6,250
)
 
45.31

 

 

 
(37,500
)
 
43.56

Outstanding December 31
833,630

 
49.92

 
860,274

 
46.58

 
748,208

 
44.79

Exercisable at December 31
375,255

 
46.68

 
435,899

 
45.33

 
380,708

 
44.85



The intrinsic value of options exercised in 2016, 2015, and 2014, was $3.4 million, $1.5 million and $2.0 million, respectively. The intrinsic value of options outstanding and exercisable at year end 2016 was $13.9 million and $7.5 million, respectively. The intrinsic value measures the difference between the options’ exercise price and the closing share price quoted by the New York Stock Exchange as of the date of measurement. The date of exercise was the measurement date for shares exercised during the period. At December 30, 2016, the final trading day of calendar 2016, the closing price of $66.61 per share was used for the calculation of aggregate intrinsic value of options outstanding and exercisable at that date. The weighted average remaining contractual life of the Company’s exercisable and outstanding options at December 31, 2016 are 6.4 and 7.5 years, respectively.